EZZ Life Science Holdings (ASX:EZZ) EBIT: A$5.89 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:EZZ EZZ Life Science Holdings Ltd ASX:EZZ
49 GF Score
Price A$0.48
GF Value A$1.45
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is EZZ Life Science Holdings EBIT?

EZZ Life Science Holdings ASX:EZZ +3.23% 49 EBIT is A$5.89 Mil as of Dec. 2025. GuruFocus rates ASX:EZZ with a GF Score™ of 49/100 and a GF Value™ of A$1.45 (Possible Value Trap). The stock has 4 warning signs investors should review.

EZZ Life Science Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$0.07 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$5.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. EZZ Life Science Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. EZZ Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 63.81%.

EZZ Life Science Holdings  (ASX:EZZ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EZZ Life Science Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-0.214 * ( 1 - 100% )/( (9.231 + 15.208)/ 2 )
=-0/12.2195
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=33.957 - 3.877 - ( 20.849 - max(0, 5.726 - 33.038+20.849))
=9.231

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32.603 - 3.92 - ( 13.475 - max(0, 4.797 - 31.529+13.475))
=15.208

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

EZZ Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.13/( ( (0.89 + max(6.678, 0)) + (0.668 + max(13.381, 0)) )/ 2 )
=0.13/( ( 7.568 + 14.049 )/ 2 )
=0.13/10.8085
=1.20 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.469 + 2.433 + 5.198) - (3.877 + 1.47 + 0.075)
=6.678

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.071 + 3.73 + 7.253) - (3.92 + 0.672 + 0.081)
=13.381

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

EZZ Life Science Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=5.89/9.230
=63.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EZZ Life Science Holdings EBIT Related Terms

EZZ Life Science Holdings EBIT Historical Data

* Premium members only.

The historical data trend for EZZ Life Science Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EZZ Life Science Holdings EBIT Chart

EZZ Life Science Holdings Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial 2.75 1.78 4.91 9.98 10.59

EZZ Life Science Holdings Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.54 8.44 4.77 5.83 0.07

ASX:EZZ vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, EZZ Life Science Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EZZ Life Science Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's EV-to-EBIT falls into.


ASX:EZZ
49GF Score
EZZ Life Science Holdings Ltd ASX:EZZ
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EZZ Life Science Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$5.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$5.89 Mil mean?
EZZ Life Science Holdings (ASX:EZZ) has a EBIT of A$5.89 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on EZZ Life Science Holdings.
Is EZZ Life Science Holdings' EBIT too high?
EZZ Life Science Holdings' current EBIT is A$5.89 Mil. Overall, EZZ Life Science Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EZZ Life Science Holdings' EBIT compare to VRTX and REGN?
EZZ Life Science Holdings' EBIT of A$5.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on EZZ Life Science Holdings. EZZ Life Science Holdings's current EBIT is A$5.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EZZ Life Science Holdings stock overvalued right now?
Based on GuruFocus' analysis, EZZ Life Science Holdings (ASX:EZZ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.45, compared to a current price of A$0.48 — trading 66.9% below its estimated fair value. The current EBIT is A$5.89 Mil. EZZ Life Science Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For EZZ Life Science Holdings (ASX:EZZ), the current EBIT is A$5.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EZZ Life Science Holdings (ASX:EZZ) Overvalued in 2026?

Based on GuruFocus' analysis, EZZ Life Science Holdings stock appears to be undervalued. The current stock price of A$0.48 is trading 66.9% below its estimated GF Value™ of A$1.45. GuruFocus considers EZZ Life Science Holdings to be Possible Value Trap.

Key valuation signals for ASX:EZZ:

  • EBIT: A$5.89 Mil
  • GF Value™: A$1.45 vs. price of A$0.48 (66.9% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the ASX:EZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EZZ Life Science Holdings Business Description

Address 55-59 Parramatta Road, Shop 1, Lidcombe, NSW, AUS, 2141
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
49GF Score

Get the complete analysis for ASX:EZZ

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price
A$1.45
GF Value